Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03488667 · ClinicalTrials.gov registry record · Phase 2
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
A Phase 2 study of Adenocarcinoma and Stomach Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03488667 is a Phase 2 study of Adenocarcinoma and Stomach Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 40 participants, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03488667, a Phase 2 study of Adenocarcinoma and Stomach Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
Conditions Studied
Interventions
- DRUG Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
- DRUG Adjuvant Treatment - mFOLFOX & Pembrolizumab
Study Locations (1)
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03488667
The ClinicalTrials.gov registry entry for NCT03488667 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (58% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab is the first listed.
NCT03488667 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03488667 about?
NCT03488667 is a clinical study titled "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma". To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
What is the current status of trial NCT03488667?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-06-27. Estimated completion is 2025-04-30.
What conditions does trial NCT03488667 study?
This clinical trial studies the following conditions: Adenocarcinoma, Stomach Cancer, Gastro-esophageal Junction Cancer.
What interventions are being tested in trial NCT03488667?
The interventions under investigation include: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab (DRUG), Adjuvant Treatment - mFOLFOX & Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03488667?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03488667 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
COMPLETED · Phase 2
-
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.